Overview Request Sample Pages Request Customization Download PDF
You are viewing: South Korea Preimplantation Genetic Testing Market analysis

The South Korea Preimplantation Genetic Testing Market was valued at $4.9 Million in 2025 and projected to reach to $8.2 Million by 2030, representing a compound annual growth rate of 11.0%. South Korea's preimplantation genetic testing market is poised for sustained growth through 2030, supported by increasing prevalence of advanced maternal age, rising infertility rates, and heightened demand for genetic disease screening among fertility patients.

South Korea Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Preimplantation Genetic Testing Market Trends and Insights

  • This 11.0% compound annual growth rate reflects South Korea's advanced healthcare infrastructure, high adoption of assisted reproductive technologies, and increasing awareness of genetic screening benefits among fertility clinics and patients.
  • South Korea's aging population and declining birth rates have intensified demand for optimized fertility treatments, positioning PGT as a critical tool in reproductive medicine. The South Korea market benefits from strong regulatory frameworks, sophisticated laboratory capabilities, and significant investment in biotechnology innovation.
  • South Korea's fertility sector has embraced PGT adoption to improve implantation success rates and reduce miscarriage risks, driving clinical demand.
  • Between 2025 and 2030, South Korea is expected to see accelerated market penetration as reimbursement policies evolve and patient education campaigns expand awareness of genetic testing advantages in assisted reproduction..

Key Market Statistics

  • CAGR (2025-2030) 11.0% CAGR
  • Market Size, 2025 ~USD 4.9 Million
  • Forecast, 2030 ~USD 8.2 Million
  • Country South Korea

South Korea Preimplantation Genetic Testing Market Overview

Market Valuation Growth :

South Korea's PGT market is valued at $4.9 million in 2025, with projections reaching $8.2 million by 2030, representing a strong 11% CAGR driven by technological advancement and increased fertility clinic adoption.

Advanced Healthcare Infrastructure :

South Korea's world-class medical facilities and high-tech diagnostic capabilities position it as a leader in reproductive genetics, with fertility clinics increasingly integrating PGT into standard assisted reproductive technology protocols.

Rising Patient Awareness :

Growing consumer education about genetic screening benefits and hereditary disease prevention is driving demand among South Korean patients seeking advanced fertility solutions and healthy pregnancy outcomes.

Regulatory Support & Innovation :

South Korea's progressive regulatory environment and investment in biotech innovation create favorable conditions for PGT service expansion and the introduction of next-generation genetic testing technologies.

South Korea Preimplantation Genetic Testing Market Dynamics

  • The country's robust healthcare system and high penetration of assisted reproductive technologies create an ideal environment for PGT adoption. Key growth drivers include expanding fertility clinic networks, enhanced reimbursement policies, and growing patient preference for preventive genetic screening.
  • As South Korean consumers increasingly prioritize reproductive health and genetic safety, combined with continuous technological improvements in testing accuracy and cost reduction, the market is expected to maintain its 11% annual growth trajectory through the forecast period..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • South Korea's PGT market is valued at $4.9 million in 2025 and is forecast to grow to $8.2 million by 2030, representing an 11.0% CAGR.
      • South Korea's advanced healthcare infrastructure and high fertility clinic density support rapid adoption of preimplantation genetic testing technologies.
      • South Korea's demographic challenges, including an aging population and low birth rates, drive demand for optimized assisted reproductive procedures incorporating PGT.
      • South Korea's regulatory environment and biotechnology expertise position the country as a regional leader in genetic testing innovation and clinical implementation.

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      South Korea Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      Target Audience

      • Fertility Clinic Operators : South Korean fertility clinics need market data to evaluate PGT service expansion opportunities, understand competitive positioning, and make informed decisions about technology investments and service offerings.
      • Diagnostic Laboratory Companies : Genetic testing and diagnostic firms require South Korea-specific market intelligence to assess market entry strategies, identify growth opportunities, and understand local demand for PGT services and technologies.
      • Medical Device & Biotech Manufacturers : Companies developing PGT equipment and genetic analysis platforms need South Korea market insights to guide product localization, regulatory compliance, and go-to-market strategies in this advanced healthcare market.
      • Healthcare Investors & Consultants : Investment firms and management consultants require detailed South Korea market analysis to evaluate investment opportunities, assess market viability, and develop strategic recommendations for healthcare clients.
      • Healthcare Policy & Insurance Organizations : South Korean health insurers and policy makers need market data to understand PGT adoption trends, assess reimbursement implications, and develop evidence-based coverage policies for genetic testing services.

      Key Companies in the South Korea Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Market-Specific Growth Projections : Access detailed South Korea-specific forecasts showing 11% CAGR growth from $4.9M to $8.2M, enabling accurate business planning and investment decisions tailored to this high-growth Asian market.
      • Competitive Landscape Intelligence : Understand South Korea's unique fertility clinic ecosystem, key market players, and competitive positioning within the region's advanced healthcare infrastructure to identify partnership and expansion opportunities.
      • Regulatory & Reimbursement Insights : Gain critical knowledge of South Korea's healthcare policies, insurance coverage for PGT services, and regulatory requirements specific to genetic testing implementation in fertility clinics.
      • Patient Demographics & Demand Drivers : Analyze South Korea-specific demographic trends including advanced maternal age, infertility prevalence, and consumer awareness levels to tailor marketing strategies and service offerings effectively.
      • Technology Adoption Trends : Identify South Korea's adoption patterns for next-generation sequencing, AI-driven genetic analysis, and emerging PGT technologies to align product development and commercialization strategies with local market needs.

      Frequently asked questions

      What is the current market size of preimplantation genetic testing in South Korea?

      South Korea's preimplantation genetic testing market was valued at $4.9 million in 2025 and is expected to reach $8.2 million by 2030.

      What is the projected growth rate for South Korea's PGT market?

      South Korea's PGT market is projected to grow at an 11.0% compound annual growth rate from 2025 to 2030.

      Why is South Korea's PGT market experiencing rapid growth?

      South Korea's market growth is driven by advanced healthcare infrastructure, high fertility clinic adoption rates, demographic pressures from aging populations, and increasing patient awareness of genetic screening benefits.

      What factors support PGT adoption in South Korea's fertility sector?

      South Korea's strong regulatory framework, sophisticated laboratory capabilities, biotechnology expertise, and emphasis on improving implantation success rates support widespread PGT adoption among fertility clinics.

      How does South Korea's demographic situation influence the PGT market?

      South Korea's aging population and declining birth rates create urgency for optimized fertility treatments, making PGT an essential tool for improving reproductive outcomes and reducing miscarriage risks.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status